If you’re on the GLP-1 medication tirzepatide and someone in your life is still side-eyeing it as “just a weight loss drug,” here’s a study to send them.
Researchers just published a large real-world analysis in The BMJ showing that people with type 2 diabetes who started tirzepatide had a third fewer major cardiovascular events, heart attacks, strokes, and deaths, compared to folks who started a standard diabetes pill instead.
Not in a lab. Not in mice. In actual patients, tracked through real medical claims.
A Real-World Test, Not a Lab Study
The study followed nearly 53,000 adults with type 2 diabetes who also had established heart disease. So this wasn’t a low-risk group to begin with.
Everyone in the study either started tirzepatide or started sitagliptin, an older diabetes medication that’s already been shown in prior research to be basically neutral for the heart, neither helping nor hurting. This allowed researchers to isolate what tirzepatide itself is doing, rather than just comparing it to nothing.
The Numbers
After weighting the two groups so they were as similar as possible in age, health history, and other medications, the researchers tracked what happened over the following year.
The people on tirzepatide had a 2.9% risk of a major cardiovascular event. The people on sitagliptin had a 4.4% risk. When you do the math, tirzepatide came out with a 32% lower hazard of a major cardiac event overall.
Where the Benefit Actually Came From
Break the results down even further, and the heart attack numbers stand out with a 33% lower risk of heart attack in the tirzepatide group. All-cause mortality was 45% lower.
Stroke risk didn’t show a significant difference between the two groups, but between fewer heart attacks and fewer deaths, tirzepatide came out ahead by a wide margin. There was even a secondary finding that people on tirzepatide had noticeably fewer infections requiring hospitalization, which researchers flagged as worth digging into further.
More Research Is Needed
To be perfectly clear, this was an observational study. That means the researchers watched what happened to people already prescribed these medications in the real world rather than randomly assigning people to each drug in a controlled trial.
This design is a great way to capture how a medication performs outside the tidy conditions of a clinical trial. Still, it also means the researchers can’t fully rule out that something else about the people who were prescribed tirzepatide, rather than the drug itself, explains part of the gap.
The study’s own authors flagged this directly, noting the mortality numbers in particular could be influenced by differences between the two groups that weren’t fully accounted for. The follow-up window was also short, a median of under six months on treatment, so this is a one-year snapshot, not a decade-long picture. And more research is needed.
A Third Fewer Cardiac Events
However, keep in mind that being an observational study doesn’t erase this remarkable finding. This wasn’t a small bump in the signal. A third fewer major cardiac events, in a group of folks who already had heart disease, tracked using real-world data, is nothing to sneeze at. We suspected GLP-1s were doing this work, but we now have some of our first data confirming it.
Tirzepatide already had a reputation as one of the most effective tools available for managing obesity through weight loss and blood sugar control. This adds a heart-protective angle that’s backed by tens of thousands of real patients.
For anyone who started this medication purely chasing a number on the scale, this is the kind of study that should reframes what you’re actually doing every time you take your dose. You’re not just managing weight. You’re likely doing meaningful, measurable work to protect your heart too.
Reference: Kruger N, Schneeweiss S, Wang S V. Tirzepatide and the risk of atherosclerotic cardiovascular events: population-based cohort study, BMJ 2026; 394 :e100011 doi:10.1136/bmj-2026-100011
